Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis

Robert Chiesa, Annalisa Ruggeri, A. L. Paviglianiti, Marco Zecca, Marta Gónzalez-Vicent, Victoria Bordon, Jerry Stein, Sarah Lawson, Sophie Dupont, Edoardo Lanino, Manuel Abecasis, Amal Al Seraihy, Chantal Kenzey, Marc Bierings, Franco Locatelli, E. Gluckman, Ansgar Schulz, Andrew Gennery, Kristin Page, J. KurtzbergVanderson Rocha

Research output: Contribution to journalArticle

Abstract

Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for most children with osteopetrosis (OP). Timing of HSCT is critical; therefore, umbilical cord blood transplantation (UCBT) is an attractive option. We analyzed outcomes after UCBT in 51 OP children. Median age at UCBT was 6 months. Seventy-seven percent of the cord blood grafts had 0 or 1 HLA disparity with the recipient. Conditioning regimen was myeloablative (mostly busulfan-based in 84% and treosulfan-based in 10%). Antithymocyte globulin was given to 90% of patients. Median number of total nucleated and CD34+ cells infused was 14 × 107/kg and 3.4 × 105/kg, respectively. Median follow-up for survivors was 74 months. Cumulative incidence (CI) of neutrophil recovery was 67% with a median time to recovery of 23 days; 33% of patients had graft failure, 81% of engrafted patients had full donor engraftment, and 19% had mixed donor chimerism. Day 100 CI of acute graft-versus-host disease (grades II to IV) was 31% and 6-year CI of chronic graft-versus-host disease was 21%. Mechanical ventilation was required in 28%, and veno-occlusive disease was diagnosed in 16% of cases. Six-year overall survival rate was 46%. Comparative studies with other alternative donors should be performed to evaluate whether UCBT remains a valid alternative for children with OP without an HLA-matched donor.

Original languageEnglish
Pages (from-to)1997-2002
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Osteopetrosis
Fetal Blood
Transplantation
Tissue Donors
treosulfan
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Incidence
Transplants
Busulfan
Chimerism
Antilymphocyte Serum
Artificial Respiration
Survivors
Neutrophils
Survival Rate

Keywords

  • Osteopetrosis
  • Stem cell transplantation
  • Umbilical cord blood transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis. / Chiesa, Robert; Ruggeri, Annalisa; Paviglianiti, A. L.; Zecca, Marco; Gónzalez-Vicent, Marta; Bordon, Victoria; Stein, Jerry; Lawson, Sarah; Dupont, Sophie; Lanino, Edoardo; Abecasis, Manuel; Al Seraihy, Amal; Kenzey, Chantal; Bierings, Marc; Locatelli, Franco; Gluckman, E.; Schulz, Ansgar; Gennery, Andrew; Page, Kristin; Kurtzberg, J.; Rocha, Vanderson.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 11, 01.11.2016, p. 1997-2002.

Research output: Contribution to journalArticle

Chiesa, R, Ruggeri, A, Paviglianiti, AL, Zecca, M, Gónzalez-Vicent, M, Bordon, V, Stein, J, Lawson, S, Dupont, S, Lanino, E, Abecasis, M, Al Seraihy, A, Kenzey, C, Bierings, M, Locatelli, F, Gluckman, E, Schulz, A, Gennery, A, Page, K, Kurtzberg, J & Rocha, V 2016, 'Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis', Biology of Blood and Marrow Transplantation, vol. 22, no. 11, pp. 1997-2002. https://doi.org/10.1016/j.bbmt.2016.07.015
Chiesa, Robert ; Ruggeri, Annalisa ; Paviglianiti, A. L. ; Zecca, Marco ; Gónzalez-Vicent, Marta ; Bordon, Victoria ; Stein, Jerry ; Lawson, Sarah ; Dupont, Sophie ; Lanino, Edoardo ; Abecasis, Manuel ; Al Seraihy, Amal ; Kenzey, Chantal ; Bierings, Marc ; Locatelli, Franco ; Gluckman, E. ; Schulz, Ansgar ; Gennery, Andrew ; Page, Kristin ; Kurtzberg, J. ; Rocha, Vanderson. / Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis. In: Biology of Blood and Marrow Transplantation. 2016 ; Vol. 22, No. 11. pp. 1997-2002.
@article{deef3755bd8d4391a0571e56c0ce3ff7,
title = "Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis",
abstract = "Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for most children with osteopetrosis (OP). Timing of HSCT is critical; therefore, umbilical cord blood transplantation (UCBT) is an attractive option. We analyzed outcomes after UCBT in 51 OP children. Median age at UCBT was 6 months. Seventy-seven percent of the cord blood grafts had 0 or 1 HLA disparity with the recipient. Conditioning regimen was myeloablative (mostly busulfan-based in 84{\%} and treosulfan-based in 10{\%}). Antithymocyte globulin was given to 90{\%} of patients. Median number of total nucleated and CD34+ cells infused was 14 × 107/kg and 3.4 × 105/kg, respectively. Median follow-up for survivors was 74 months. Cumulative incidence (CI) of neutrophil recovery was 67{\%} with a median time to recovery of 23 days; 33{\%} of patients had graft failure, 81{\%} of engrafted patients had full donor engraftment, and 19{\%} had mixed donor chimerism. Day 100 CI of acute graft-versus-host disease (grades II to IV) was 31{\%} and 6-year CI of chronic graft-versus-host disease was 21{\%}. Mechanical ventilation was required in 28{\%}, and veno-occlusive disease was diagnosed in 16{\%} of cases. Six-year overall survival rate was 46{\%}. Comparative studies with other alternative donors should be performed to evaluate whether UCBT remains a valid alternative for children with OP without an HLA-matched donor.",
keywords = "Osteopetrosis, Stem cell transplantation, Umbilical cord blood transplantation",
author = "Robert Chiesa and Annalisa Ruggeri and Paviglianiti, {A. L.} and Marco Zecca and Marta G{\'o}nzalez-Vicent and Victoria Bordon and Jerry Stein and Sarah Lawson and Sophie Dupont and Edoardo Lanino and Manuel Abecasis and {Al Seraihy}, Amal and Chantal Kenzey and Marc Bierings and Franco Locatelli and E. Gluckman and Ansgar Schulz and Andrew Gennery and Kristin Page and J. Kurtzberg and Vanderson Rocha",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.bbmt.2016.07.015",
language = "English",
volume = "22",
pages = "1997--2002",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis

AU - Chiesa, Robert

AU - Ruggeri, Annalisa

AU - Paviglianiti, A. L.

AU - Zecca, Marco

AU - Gónzalez-Vicent, Marta

AU - Bordon, Victoria

AU - Stein, Jerry

AU - Lawson, Sarah

AU - Dupont, Sophie

AU - Lanino, Edoardo

AU - Abecasis, Manuel

AU - Al Seraihy, Amal

AU - Kenzey, Chantal

AU - Bierings, Marc

AU - Locatelli, Franco

AU - Gluckman, E.

AU - Schulz, Ansgar

AU - Gennery, Andrew

AU - Page, Kristin

AU - Kurtzberg, J.

AU - Rocha, Vanderson

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for most children with osteopetrosis (OP). Timing of HSCT is critical; therefore, umbilical cord blood transplantation (UCBT) is an attractive option. We analyzed outcomes after UCBT in 51 OP children. Median age at UCBT was 6 months. Seventy-seven percent of the cord blood grafts had 0 or 1 HLA disparity with the recipient. Conditioning regimen was myeloablative (mostly busulfan-based in 84% and treosulfan-based in 10%). Antithymocyte globulin was given to 90% of patients. Median number of total nucleated and CD34+ cells infused was 14 × 107/kg and 3.4 × 105/kg, respectively. Median follow-up for survivors was 74 months. Cumulative incidence (CI) of neutrophil recovery was 67% with a median time to recovery of 23 days; 33% of patients had graft failure, 81% of engrafted patients had full donor engraftment, and 19% had mixed donor chimerism. Day 100 CI of acute graft-versus-host disease (grades II to IV) was 31% and 6-year CI of chronic graft-versus-host disease was 21%. Mechanical ventilation was required in 28%, and veno-occlusive disease was diagnosed in 16% of cases. Six-year overall survival rate was 46%. Comparative studies with other alternative donors should be performed to evaluate whether UCBT remains a valid alternative for children with OP without an HLA-matched donor.

AB - Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for most children with osteopetrosis (OP). Timing of HSCT is critical; therefore, umbilical cord blood transplantation (UCBT) is an attractive option. We analyzed outcomes after UCBT in 51 OP children. Median age at UCBT was 6 months. Seventy-seven percent of the cord blood grafts had 0 or 1 HLA disparity with the recipient. Conditioning regimen was myeloablative (mostly busulfan-based in 84% and treosulfan-based in 10%). Antithymocyte globulin was given to 90% of patients. Median number of total nucleated and CD34+ cells infused was 14 × 107/kg and 3.4 × 105/kg, respectively. Median follow-up for survivors was 74 months. Cumulative incidence (CI) of neutrophil recovery was 67% with a median time to recovery of 23 days; 33% of patients had graft failure, 81% of engrafted patients had full donor engraftment, and 19% had mixed donor chimerism. Day 100 CI of acute graft-versus-host disease (grades II to IV) was 31% and 6-year CI of chronic graft-versus-host disease was 21%. Mechanical ventilation was required in 28%, and veno-occlusive disease was diagnosed in 16% of cases. Six-year overall survival rate was 46%. Comparative studies with other alternative donors should be performed to evaluate whether UCBT remains a valid alternative for children with OP without an HLA-matched donor.

KW - Osteopetrosis

KW - Stem cell transplantation

KW - Umbilical cord blood transplantation

UR - http://www.scopus.com/inward/record.url?scp=84992374778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992374778&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.07.015

DO - 10.1016/j.bbmt.2016.07.015

M3 - Article

VL - 22

SP - 1997

EP - 2002

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -